Medication therapies directed against the epidermal development aspect pathway and related molecular targets play an extremely important role in malignancy therapy and represent nearly all oncology therapies in advancement, but usually do not provide advantage for all individuals. The granting of the patent recognizes our exclusive approach and development in this exciting region of molecular diagnostics, commented David Brunel, Biodesix CEO. We are focused on applying our technology to build up clinically meaningful checks that enhance scientific decision making and individual care.This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an unbiased news service editorially, is an application of the Kaiser Family members Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
Cancer tumor survivors have unique and long-term cancer-specific side effects. Patients surviving childhood Hodgkin disease suffer strokes later in life at rates about 4 situations that of the general population, UT Southwestern Medical Center researchers have got found. Principal investigator Dr. Daniel Bowers, associate professor of pediatrics, and additional UT Southwestern experts identified the link using patient information from a national database of long-term childhood malignancy survivors.